MSD
Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer
May 11, 2020Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer
Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …
MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population
April 3, 2020Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma
MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …
Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
March 12, 2020Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …
New Keytruda dosing schedule rejected in six cancers by the FDA
February 20, 2020Sales and Marketing Cancer, FDA, MSD, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has been stopped in its tracks by the FDA after the US regulator rejected its application …
Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer
January 16, 2020Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza
It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …
MSD’s Keytruda chalks up bladder cancer approval in the US
January 9, 2020Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …
Bittersweet Phase 3 Keytruda data hits one of two goals in extensive stage small cell lung cancer
January 7, 2020Manufacturing and Production, Research and Development MSD, keytruda
MSD has lifted the curtain on new Phase 3 data on the efficacy of its blockbuster immunotherapy Keytruda, in combination …
MSD set to acquire ArQule in deal worth up to $2.7 billion
December 10, 2019Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma
MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …
Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals
November 19, 2019Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma
MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …
Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3
November 19, 2019Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat
MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …
MSD’s proposed sale of French manufacturing plant puts over 200 jobs in jeopardy
November 14, 2019Manufacturing and Production France, MSD, pharma
MSD has announced its plans to put its Centre de Mirabel production facility in Riom, France up for sale – …
MSD secures EU approval for its Zaire Ebola vaccine Ervebo
November 12, 2019Manufacturing and Production, Sales and Marketing Ebola, Ervebo, MSD, pharma
MSD has scored approval from the European Commission for Ervebo, the company’s Zaire Ebola vaccine, for the prevention of Ebola …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma
September 4, 2019Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
FDA warns three Hepatitis C drugs may worsen liver function in some rare cases
August 29, 2019Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health
The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
